Hypoglycemic agents such as pioglitazone reduce the risk of stroke recurrence by activating PPARγ signaling in adipocytes, immune and endothelial cells, and other tissues (Kernan et al., 2016; Yaghi et al., 2018). This evidence concerns the gene PPARG and stroke disorder.